Pure Red Cell Aplasia

  • Robert T. MeansJr.Email author


The term “pure red cell aplasia” (PRCA) describes normocytic normochromic anemia associated with severe reticulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow. PRCA is not a single disorder but includes congenital diseases caused by mutations in genes regulating ribosomal or mitochondrial proteins (Diamond-Blackfan anemia and Pearson syndrome), acquired myelodysplastic syndromes with the morphologic features of PRCA, as well as immune-mediated syndromes. Primary acquired PRCA, the best-known member of the class of PRCA disorders, is an autoimmune disorder, frequently antibody-mediated. Secondary acquired PRCA may be associated with collagen vascular/autoimmune disorders; lymphoproliferative disorders; infections, particularly B19 parvovirus; thymoma and other solid tumors; or treatment with drugs. The therapeutic approach in most cases of primary or secondary acquired PRCA is immunosuppression, but specific pathogenic subtypes are associated with specific therapeutic approaches. The single most effective immunosuppressive agent appears to be cyclosporine A, alone or with concurrent corticosteroids.


Pure red cell aplasia Anemia Parvovirus Bone marrow morphology Thymoma Immunosuppression 


  1. 1.
    Means RT. Pure red cell aplasia. Blood. 2016;128(21):2504–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Arbiv OA, Cuvelier G, Klaassen RJ, et al. Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia. Clin Genet. 2018;93(2):320–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54(2):273–8.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Cerchione C, Catalano L, Cerciello G, et al. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Ann Hematol. 2015;94(3):531–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Dessypris EN. Pure red cell aplasia. Baltimore: Johns Hopkins University Press; 1988.Google Scholar
  6. 6.
    Au WY, Cheng VC, Wan TS, Ma SK. Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts. Ann Hematol. 2004;83(10):670–1.PubMedCrossRefGoogle Scholar
  7. 7.
    Masuda M, Teramura M, Matsuda A, et al. Clonal T cells of pure red-cell aplasia. Am J Hematol. 2005;79(4):332–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Means RT, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A: in vitro correlation of clinical response. Br J Haematol. 1991;78:114–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Peschle C, Marmont AM, Marone G, Genovese A, Sasso GF, Condorelli M. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol. 1975;30(4):411–7.PubMedCrossRefGoogle Scholar
  11. 11.
    van den Akker M, Dror Y, Odame I. Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease. Acta Paediatr. 2014;103(7):e288–94.PubMedGoogle Scholar
  12. 12.
    Dessypris EN, McKee CL Jr, Metzantonakis C, Teliacos M, Krantz SB. Red cell aplasia and chronic granulocytic leukaemia. Br J Haematol. 1981;48(2):217–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Chalayer E, Costedoat-Chalumeau N, Beyne-Rauzy O, et al. Bone marrow involvement in systemic lupus erythematosus. QJM. 2017;110(11):701–11.PubMedGoogle Scholar
  14. 14.
    Parida PK, Shukla SN, Talati SS, Parikh SK. Acquired pure red cell aplasia in a patient of rheumatoid arthritis. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):255–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Cavazzana I, Ceribelli A, Franceschini F, Cattaneo R. Unusual association between pure red cell aplasia and primary Sjogren’s syndrome: a case report. Clin Exp Rheumatol. 2007;25(2):309–11.PubMedGoogle Scholar
  16. 16.
    Arcasoy MO, Chao NJ. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol. 2005;78(2):161–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Kiely PD, McGuckin CP, Collins DA, Bevan DH, Marsh JC. Erythrocyte aplasia and systemic lupus erythematosus. Lupus. 1995;4(5):407–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89(11):1055–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Hirokawa M, Sawada K, Fujishima N, et al. Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Am J Hematol. 2009;84(3):144–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Frickhofen N, Chen ZJ, Young NS, Cohen BJ, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol. 1994;87(4):818–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330(17):1192–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Hirokawa M, Sawada K, Fujishima N, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015;169(6):879–86.PubMedCrossRefGoogle Scholar
  24. 24.
    Bernard C, Frih H, Pasquet F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016;15(1):82–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Aksoy M, Dincol K, Agun T, Erdem S, Dincol G. Haematological effects of chronic benzene poisoning in 217 workers. Br J Ind Med. 1971;28:296–302.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Jurgensen JC, Abrahams JP, Hardy WW. Erythroid aplasia after halothane hepatitis: report of a case. Am J Dig Dis. 1970;15:577–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Gasser C. Akute Erythroblastopenie: 10 Falle aplasticher Erythroblastenkrisen mit Riesenproerythroblasten bei allergish toxischen Zustandsbildern. Helv Pediatr Acta. 1949;4:107.Google Scholar
  28. 28.
    Estavoyer JM, Singer P, Broda C, Baufle GH. Toxicite hematologique du thiamphenicol: a propos de deux observations d’erythroblastopenie aigue. Sem Hop. 1981;57:1970–2.PubMedGoogle Scholar
  29. 29.
    Dessypris EN, Redline S, Harris JW, Krantz SB. Diphenylhydantoin-induced pure red cell aplasia. Blood. 1985;65:789–94.PubMedGoogle Scholar
  30. 30.
    Mariette X, Mitjavila MT, Moulinie JP, et al. Rifampicin-induced pure red cell aplasia. Am J Med. 1989;87(4):459–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Carson KR, Evens AM, Bennett CL, Luminari S. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18(3):467–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Bennett CL, Starko KM, Thomsen HS, et al. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. A report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012;27(12):1697–703.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160(6):798–805.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505–14.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87(7):3000–6.PubMedGoogle Scholar
  36. 36.
    Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11):4831–8.PubMedGoogle Scholar
  37. 37.
    Yoshida S, Konishi T, Nishizawa T, Yoshida Y. Effect of tacrolimus in a patient with pure red-cell aplasia. Clin Lab Haematol. 2005;27(1):67–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Jiang H, Zhang H, Wang Y, et al. Sirolimus for the treatment of multi-resistant pure red cell aplasia. Br J Haematol. 2018;
  39. 39.
    Auner HW, Wolfer A, Beham-Schmid C, Strunk D, Linkesch W, Still H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. Br J Haematol. 2002;116:727–8.PubMedCrossRefGoogle Scholar
  40. 40.
    D’Arena G, Vigliotti ML, Dell’Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol. 2009;82(3):235–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4(5):264–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Freund LG, Hippe E, Strandgaard S, Pelus LM, Erslev AJ. Complete remission in pure red cell aplasia after plasmapheresis. Scand J Haematol. 1985;35(3):315–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Zaentz DS, Krantz SB, Sears DA. Studies on pure red cell aplasia. VII. Presence of proerythroblasts and response to splenectomy: a case report. Blood. 1975;46(2):261–70.PubMedGoogle Scholar
  44. 44.
    Kochethu G, Baden HS, Jaworska E, Chang J, Chopra R. Reduced intensity conditioning bone marrow transplantation for pure red cell aplasia: successful outcome but difficult post transplant course. Bone Marrow Transplant. 2005;36(1):81–2.PubMedCrossRefGoogle Scholar
  45. 45.
    Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968–77.PubMedCrossRefGoogle Scholar
  46. 46.
    Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006;135(3):405–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008;93(1):27–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2016;43(1):3–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81(8):727–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Shimizu H, Saitoh T, Ota F, et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126(2):114–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Ann Hematol. 2007;86(4):233–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Moussa M, Hassan MF. Newly diagnosed adult-onset Still’s disease with pure red cell aplasia in pregnancy. Arch Gynecol Obstet. 2014;290(1):195–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Kashyap R, Pradhan M. Maternal and fetal outcome in pregnancy-associated pure red cell aplasia. J Obstet Gynaecol. 2010;30(7):733–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.James H. Quillen College of Medicine, East Tennessee State UniversityJohnson CityUSA

Personalised recommendations